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RESUMEN 
 
 
La leishmaniasis es una parasitosis endémica y ampliamente distribuida en zonas tropicales y 
subtropicales en el mundo. Se considera que la incidencia de esta infección podría 
incrementarse por la progresiva urbanización, cuya consecuencia es el incremento en la 
exposición de las personas a la picadura  del  vector.  Actualmente,  en países endémicos, 
incluido el Ecuador, el tratamiento de elección contra leishmaniasis es la aplicación 
intramuscular de compuestos amoniacales. Sin embargo este  tratamiento  está asociado a una 
baja  adherencia dado el requerimiento de múltiples aplicaciones de la medicina, la toxicidad y 
la resistencia desarrollada por los parásitos. Estas características incrementan el interés de 
desarrollar nuevas estrategias terapéuticas contra la infección. Recientemente,  algunos  
sistemas de suministro de drogas,  tales como las nano - partículas, se han utilizado in vivo e 
in vitro,  con  diferentes  medicamentos de aplicación local. El objetivo del presente trabajo 
fue  evaluar la eficacia de una  nanoemulsión tópica de  antimonato de meglumina en úlceras 
de leishmaniasis cutánea en un modelo murino. Se infectó  55 ratones y se destinó 
aleatoriamente animales infectados a distintos grupos de tratamiento. Seis ratones fueron 
tratados únicamente con crema, doce ratones recibieron la nanoemulsión sin antimonato de 
meglumina  y  21 ratones recibieron la nanoemulsión con antimonato de meglumina. El grupo 
control (16 ratones) fue tratado con el medicamento original (sin nanoemulsión) vía 
intraperitoneal.  Los resultados demostraron que administración tópica de antimonato de 
meglumina en nanoemulsión causa un efecto benéfico en el control de la parasitosis y la 
curación de la úlcera, pero este efecto no tiene soporte estadístico.  
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ABSTRACT 
 
 
Leishmaniasis is an endemic disease with wide distribution in tropical and subtropical regions 
around the world. It is considered that the incidence of this infection would be increased due 
to the progressive urbanization process which consequence is the increment of the human 
exposition to vector bite. Currently, in endemic countries included Ecuador the treatment of 
choice against leishmaniasis is the intramuscular application of amoniacal compounds. 
However, this treatment is associated with poor compliance due to the requirement of multiple 
applications of medicine, toxicity and parasite resistance. These characteristics increase the the 
interest to develop new therapeutic strategies against the infection.  Recently, some drug 
delivery systems such as nanoparticles have been used in vivo and in vitro, with different 
drugs for local application. The aim of this research was to evaluate the efficacy of a topic 
nanoemulsion with meglumine antimonate applied in ulcers of cutaneous leishmaniasis in a 
murine model. Fifty five mice were infected and randomly distributed in different groups of 
treatment. Six mice were treated with cream alone, 12 mice received empty nanoemulsion and 
21 mice received nanoemulsion with meglumine antimonate. The control group (16 mice) was 
treated with the original drug (without nanoemulsion) by intraperitoneal administration. The 
results showed that the efficacy of topic administration of meglumine antimonate cause a 
benefit effect on parasitosis control and ulcer healing but this effect do not have statistic 
support.       
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INTRODUCTION 
 
Leishmaniasis is a vector-borne parasitic disease caused by the protozoa Leishmania spp. 
Leishmaniasis currently present in 88 countries throughout the world and afflicts 12 million 
people, with 350 million at risk. There are several manifestations of leishmaniasis that range 
from cutaneous to visceral forms.  The clinical presentation of this infection depends on the 
species of Leishmania and the host immune response (1).  
 
In Ecuador, leishmaniasis is considered a public health problem. It is widespread in tropical 
and subtropical areas near the Pacific Coast, Andean valleys and tropical zones in Amazon 
region. Clinical cases of leishmaniasis have been reported in 22 of 25 provinces, with 
approximately 3.1 a 4.1 million of people at risk to acquire the infection. Calvopiña et al. 
estimated that the incidence rates of leishmaniasis in Ecuador probably range from 3, 000 a 4, 
500 cases each year (2).  
 
Three forms of leishmaniasis have been reported in Ecuador, cutaneous (CL); mucocutaneous 
(MCL), and diffuse cutaneous (DCL) leishmaniasis (2). Cutaneous leishmaniasis, the most 
common form, is caused mainly by Leishmania (Viannia) panamensis and Leishmania 
(Viannia) guyanensis species and is more common in the Coast. Other forms of leishmaniasis 
affect mucosal surfaces and different organs that include bone marrow, liver, and spleen. (3). 
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The diagnosis of leishmaniasis is done on the basis of clinical presentation and histopathology. 
The most common diagnosis method used is a smear of the lesion which is stained with 
Giemsa or Wrigth. In these samples, it is possible to see extracellular parasites in amastigote 
form and vacuolated macrophages with parasites (1).  Other diagnosis methods that have been 
developed are molecular techniques like multiplex PCR, RFLP and real time PCR (1).     
 
Current therapy protocol consists of 20 daily intramuscular injections of meglumine 
antimonate (MA) in a dose equivalent to 20 mg of pentavalent antimonial (Sbv)/kg/day. The 
number of injections can be increased until the complete heal of the ulcer (4). MA is 
distributed by the Public Health Ministry of Ecuador, but the availability of the medicine is 
limited (2). Despite of the fact that Sbv have been extensively used for more than 60 years, its 
structure and mechanism of action as leishmanicida remain poorly understood (5).  
 
There are several side effects as a consequence of MA treatment. Leucopenia, agranulocytosis, 
thrombocytopenia are examples of hematologic effects that have been reported after 
antimonials application. MA toxicity also results in renal damage and increase in serum 
hepatic and pancreatic enzymes. Moreover, behavioral changes, and electrocardiographic 
(ECG) changes have been observed after this treatment (1, 4). Daily treatment with MA 
injections has a poor compliance due to the chronic use of the drug, intramuscular route of 
administration, intense pain (related to high volume for intramuscular administration), cost, 
and toxicity. A research in rural Ecuador reported that only 32.6% of patients completed the 
treatment (6). In addition, this disease affects mostly people in rural areas who usually have 
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limited access to health care centers (6). Drug discontinuation is one of the most important 
hurdles in the treatment and is probably contributing to create parasitic resistance to drug (2, 
4). Hence poor compliance, side effects, drug toxicity, and cost lead to the treatment 
discontinuation and probably affect its effectiveness.     
 
In the rural area, people use unconventional treatments to deal with the infection (6).  
Alternative fast treatments include topical application of petroleum-based products, burning of 
the ulcer, and local application of acid products. Major natural treatments are propolis, 
herbicidal agents and indigenous plants, for example: (Verbena officinalis), sangre de drago 
(Chroton lechleri), Llantén (Plantago major), etc. (6). Several researches have reported 
reduction of parasite burden using other drugs such as Amphotericin B, Azithromycin, 
Pentoxifilline, and Miltefosine Tamoxifeno, but their cost and side effects are similar to 
antimony drugs (1, 7-11). 
 
Dermal drug application is the least frequently used therapy against Leishmania ulcers, 
paramomicina for example showed contradictory results in different reports maybe it is due 
for the auto release of the lesion in the experiments done (1).  Herbal extracts applied directly 
over the cutaneous lesion in mouse model (Thymus vulgaris and Achillea millefolium) applied 
daily twice with a cotton applicator over the lesion site showed a better effect in the release of 
the lesion than MA IP application (p= 0,008 and 0,006) (11).  
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Recently, new drug delivery systems have been developed in order to improve absorption and 
minimize side effects, for example, liposomes, niosomes, microspheres, and nanoparticles are 
vesicles that could be applied topically and that can deliver active principles of medicines. 
These vesicles allow better absorption with better activity of the drugs from skin (12, 13). 
Therefore, the effectiveness of MA against Leishmania parasites could be improved through a 
topical application of vesicles with medicine while the side effects are reduced. 
 
Nanoemulsions are dispersions of oil and water which are thermodynamically stable and 
transparent. The stability of these dispersions is due by an interfacial film of surfactant and co-
surfactant molecules. At the end of the process nanoparticles have a droplet size less than 100 
nm (13, 14). 
 
Nanoparticles are made in base of spontaneous emulsification process. Currently, different 
technology developments lead mixing organic and aqueous medicine phases in homogeneous 
solutions (13). Nanoemulsion ointments have been prepared with anti-inflammatory and 
antibiotic drugs in order to test their beneficial overcome (14-16).  
 
Experiments in vitro have shown that chemical and physical features of nanoparticles depend 
on the size of the nanoparticles, the ionic charge in the surface, the surfactant and co-
surfactant reagent film (13). Moreover, nanoparticles let deliver drugs with low water 
solubility easier, in colloidal suspensions (14). For example, there are different selective 
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cyclo-oxigenase 2 inhibitors like celecoxib, non-steroidal anti-inflammatory drugs like aspirin 
and aceclofenac and antibiotics like amphotericin B that have been applied with different 
nanoemulsion formulations (14 -17).   
 
To test the skin permeability of nanoemulsions, Franz diffusion chamber have been used in 
different experiments. The experiment began with the division of the Franz chamber in donor 
and receptor sides using a prepared membrane with treated rat abdominal skin. For example, 
in Faiyaz et al. (2007) research, the experiment consist on a chamber with an effective 
diffusional area of 0.636 cm2 and 4mL of receiver chamber capacity with the dermal side of 
the rat skin faced the receiver compartment. Then, a skin stabilization process was done with 
ethanolic phosphate buffered saline solution (pH 7.4; 20:80% vol/vol). This solution was 
replaced every 30 minutes. The fluid that passed to the receiver compartment was stirred with 
a magnetic rotor (600 rpm) (16).  
 
The Franz chamber was placed in Logan transdermal permeation apparatus at 32°C. After 4.5 
hour the absorbance of the receiver fluid must be negligible indicating complete stabilization 
of rat skin. Later, 1 mL of aceclofenac nanoemulsion (20mg/mL) was placed on donor 
compartment of the Franz chamber. Then, samples were taken of the receiver chamber at 
regular time intervals to analyze the drug concentration. The cumulative drug permeated 
(mg/cm2) was calculated in each sample showing that in vitro skin permeation was highest in 
nanoemulsion formulation and lowest for conventional aceclofenac gel (p>0,05) (16). 
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The efficacy of the use of nanoparticle drug delivery systems was demonstrated in vitro, using 
Amphotericin B (AmB) against Candida albicans culture (18). Vieira D. and Carmona A. 
(2008) showed that cationic bilayer nanoparticles with dioctadecyldimethylammonium 
bromide (DODAB) plus Amphotericin B (AmB) had an inhibitory effect in Candida albicans 
growth (18). They demonstrated the anti microbial effect of a single supramolecular structure.  
These particles are the result of a self – assemble of inert carboxymethylcellulose (CMC), 
poly(diallydimethylammonium chloride) (PDDA) and AmB solubilized at the edges of 
DODAB bilayer fragments (DODAB BF) (18). 
 
The experiment consisted on leading the microorganism (1 x 106 CFU/mL) to be in contact 
with the particles for 1 hour. Then they plated 0.1mL of a 1000- fold dilution in Mili-Q water 
for each original culture in Plate Count Agar. The plates were incubated for 48 hour at 37ºC. 
Results of this experiment showed a 100% of growth inhibition with a concentration of 
AmB/DODAB BF/CMC/PDDA at PDDA concentration > 2 mg/mL (18). 
 
The efficacy of dermal application of a medicine in nanoemulsion was proved by 
Subramanian et al. (2008). They developed an inflammation model in the ear lobes of CD-1 
mice.  The dermal application of aspirin nanoemulsion caused a reduction of 70% of thickness 
of the mice ear lobes compared with a reduction of 42% of the application of aspirine 
suspension alone (14). As a result, the analysis showed that the ear tissue reduction was 
greater when the treatment consisted on nanoemulsion with aspirin vs. aspirin suspension 
alone (p<0.05) (14).  
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Faiyaz et al. (2007) showed an effective anti inflammatory effect when an aceclofenac 
nanoemulsion was applied in an edema in the hind paw of female Wistar rats (16). The edema 
was induced with carregeenan application. After 24 hours of administration of aceclofenac 
nanoemulsion the inhibition was 82.2% while the convencional aceclofenac gel only inhibited 
de edema in 41,8% (p<0.01) (16).  Additionally the authors reported there were no side effects 
in animal skin by the nanoemulsion application. (16). Data are consistent with an increased 
efficacy and low side effects of drugs administered topically in a nanoemulsion form (14).  
 
Nanoemulsions are complex mixtures of different compound and drugs that have showed to be 
best mechanisms to deliver drugs easily though the skin or mucous surface. The advantages of 
their use include their simple application, high grade of permeability through the skin, low size 
that let the particle cross the cell membrane and easy release the drug inside cells. At the same 
time, these characteristics improve the effectiveness of medicine and avoid or decrease side 
effects that drugs cause when are parenterally administered.  
 
To our knowledge, there are not reports describing the use MA in nanoemulsion preparations 
for the local treatment of CL. The aim of this study was to test the effect of a nano-emulsion 
with MA applied topically in the treatment of CL in a murine model of this parasitosis.  
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2.  OBJECTIVES 
The principal objective of this research was to evaluate the effect of a topical administration of 
meglumine antimoniate nanoemulsion in cutaneous leishmaniasis lesion using a murine 
model.  
 
Specific aims:  
• To infect susceptible BALB/c mice with Leishmania (L.) mexicana 
MHOM/BE/82/BEL-21 or Leishmania (L.) amazonensis MHOM/BR/73/M2269. 
• To treat BALB/c mice with CL with topical application of cream alone, nanoemulsion 
ointment without meglumine antimoniate, meglumine antimoniate in nanoemulsion 
ointment and intraperitoneal injections of meglumine antimonate. 
• To compare the healing rate and parasite load of BALB/c mice with CL treated with 
topical application of cream alone, empty nanoemulsion ointment, meglumine 
antimoniate in nanoemulsion ointment and intraperitoneal (IP) injections of meglumine 
antimoniate. 
• To assess the hepatic, pancreatic and renal side effects in the groups of treated animals. 
 
3.  HYPOTHESIS  
 
Topical treatment of CL with a meglumine antimoniate nanoemulsion ointment is comparable 
to the intraperitoneal treatment with the medicine alone. 
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4.  MATERIALS AND METHODS 
 
Parasites 
The strains Leishmania (L.) mexicana MHOM/BE/82/BEL-21 and Leishmania (L.) 
amazonensis MHOM/BR/73/M2269 parasites were kindly donated by Jorge Arévalo of 
Cayetano Heredia University, Tropical Diseases Institute (Lima- Peru). Parasites were 
cultured in Ushmaru Biphasic Medium supplemented with 15% of rabbit blood and 
Gentamicin (50 µg/mL) in PBS pH 7.2 with 100 U/ml penicillin and 100 mg/ml streptomycin. 
(19).  
 
Mice infection 
BALB/c mice were used in all experiments (8). Mice were used at 4–6 weeks of age.  The 
initial stock of mice was obtained from Biomedicine Center at Universidad Central del 
Ecuador (Quito- Ecuador). Animals were bred and maintained at the Animal Facility of the 
San Francisco University. 
 
BALB/c mice (n=54) were infected subcutaneously with 1 X 106 Leishmania (L.) mexicana 
MHOM/BE/82/BEL-21 (n = 24) or Leishmania (L.) amazonensis MHOM/BR/73/M2269 
promastigotes (n = 30) in log phase of growth using PBS as vehicle. The inoculation was 
applied in the base of the tail (8). Cutaneous ulcers developed within 8 weeks after initial 
inoculum. Infected mice were divided in four groups of treatment as indicated in Table 1. 
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Treatments started 10 weeks after the initial infection in order to obtain obvious and well-
defined lesions.  Animals were treated for 20 days (8). Size of ulcers was monitored every 
week and the measurements at the beginning and at the end of the treatment period were used 
for analysis. Also, animal weight was monitored every week during the time of the study. 
Topical treatment was performed with the animal immobilized in a 50 ml high -clarity 
polypropylene conical tube (BD FalconTM) for 30 minutes to avoid leaking of the cream.  
 
Lesion morphology and parasite burden 
After treatment, both macro and microscopic analysis of the lesion was carried out. Also the 
parasitic burden was evaluated. Every week cutaneous lesions were measured with a caliper 
and the widest diameter was recorded (8). Delta index of the lesion was calculated subtracting 
the final diameter measure minus the initial one. 
 
Animals were sacrificed according to standard operating procedures and strictly following 
USFQ guidelines regarding research using animal subjects. The presence of Leishmania 
parasites were determined using histological procedures (20). Briefly, 2 mm of the skin lesion 
of each mouse was preserved in 10% buffered formalin. Subsequently samples were placed in 
paraffin blocks and cut with a microtome into 4 µm think cuts. Samples were then placed in 
glass slides that were stained with Hematoxilin – Eosin (HE) following standard procedures.  
The slides were analyzed by a trained pathologist in order to describe the presence of parasites 
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in tissue sample. The characterization of histological changes was done following the criteria 
described by Massom et al. (20).  
 
The following variables were recorded in the histological analysis: presence or absence of 
ulcer, dermal atrophy, hyperkeratosis. Microscopically the presence of macrophage containing 
parasites, extracellular parasites, plasma cells, lymphocytes, eosinophils, and neutrophyls (20). 
 
For every variable a semi-quantitative scale was established (Table 2). Infiltrating leukocytes 
were evaluated by number of each cell observed by optical field (400x). Dermal atrophy was 
measured by the absence of hair follicles and glands and an increase of collagen surface. 
Hyperkeratosis was measured by the increase in the thinness of the corneal layer. A second 
part of skin lesion was conserved at -80oC for Leishmania nucleic acids extraction.  
 
DNA extraction for parasitic burden  
In order to determine the parasitic burden in infected mice, DNA from skin sample was 
extracted with High Pure PCR Template Preparation kit (Roche Applied Science) (21). To 
detect the presence of parasite specific DNA, real time PCR was performed to amplify a 120-
bp DNA fragment from Leishmania species kinetoplast minicircles (21).  
LC Fast Start DNA Master Plus SYBR Green kit (Roche Diagnostics, Quito - Ecuador) was 
used to quantify parasite DNA with a Light Cycler 2.0 instrument (Roche Applied Science, 
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Quito - Ecuador). The primers used to amplify the indicated DNA fragment were: forward, 
JW11: 5´-CCTATTTTACACCAACCCCCAGT-3´ and reverse, JW12 5´-
GGGTAGGGGCGTTCTGCGAAA-3 (15). Times and temperatures of qPCR are indicated in 
Table 3. 
 
Side effects evaluation 
In order to determine the side effects of treatments, serum concentrations of AST (Aspartate 
Aminotrasferase), ALT (Alanine Aminotransferase), Alkaline Fosfatase (Liver Function) and 
Creatinine (Kidney function) were determined (22). Briefly, at the end of treatment periods, 
animals were sacrificed as indicated previously and 0.5 to 1mL of blood was collected. Each 
analysis was done in 10 µL of serum using commercially available reagents (Orthoclinical 
diagnostics - Johnson & Johnson, Quito - Ecuador) in a Vitros 250 System dry biochemical 
analyzer (Orthoclinical diagnostics - Johnson & Johnson, Quito - Ecuador). Macroscopic 
morphology of liver, spleen, and kidneys were evaluated by visual inspection.  
 
Reagents   
Glucantime® (Meglumine antimonate) (AVENTIS PHARMA)  300 mg /ml equivalent to 85 
mg Sbv/ml was acquired at Hospital General de las Fuerzas Armadas, Quito – Ecuador. The 
nanoemulsion of MA and the empty nanoemulsions were prepared at Center of Health and 
Disease Research (University of Massachusetts LOWELL-USA) as described previously by 
Subramanian et al. with a final concentration of 280mg/mL of Glucantime® (14).  
13 
 
 
Both empty nanoemulsion and MA nanoemulsion were applied topically as creams. To obtain 
the cream, nanoemulsion were mixed with hypoallergenic cream at a ratio of 1:1 before 
application.  
 
5. RESULTS 
Effect of topical treatment with MA nanoemulsion or intraperitoneal MA 
on lesion size  
 
Macroscopic analysis 
The clinical course of lesion progression was monitored weekly. Lesions were measured with 
a caliper in millimeters as reported previously (8). Data from lesions before and after 
treatments were used for analysis. There were not obvious additional infections on skin ulcers 
by simple inspection throughout the study. In the control animals that received cream alone or 
empty nanoemulsion the size of the lesions increased with time of infection (Table 4). As 
expected, the intra-peritoneal injections of MA caused a significant decrease of lesion size 
(p=0.005). Topical treatment of cutaneous leishmaniasis with the MA nanoemulsion resulted 
in a decrease in the size of the ulcer but these results were not statistically significant (p=0.45).  
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To better analyze the effects of the different treatments a delta index of the size of the lesions 
was estimated (8). This index was calculated by subtracting the largest diameter of the ulcers 
at the end of the treatment period to the largest diameter at the beginning of the study. Delta 
values greater than cero indicate an increase in lesion size and values lower that cero indicate a 
decrease. As indicated in figure 1, there was an increase in the size of the lesions in animals 
treated with cream alone or empty nanoemulsion. Contrary, in animals treated with MA in 
nanoemulsion or with IP injections of MA there was a decrease in lesion size. A comparison 
between IP and topical treatments demonstrated that there were differences when delta lesion 
value between these treatments was compared (p< 0.05).  
 
Due to the different size of lesions within the groups before treatments it was important to 
compare the effect of the different treatments in animals with similar lesion size. A group of 
28 mice with initial lesion size between 6.0 - 7.8 mm were separately analyzed. Lesions 
greater than 6.0 mm allowed us to monitor better the changes during the treatment period. As 
was observed in all animals treated with empty nanoemulsion the size of the lesions increased 
Figure 2. For this reason these group were considered as negative control group for data 
analysis. No animals treated with cream alone were selected. On the other hand, MA IP 
decreased cutaneous lesion size in this subgroup of animals, (p<0, 01). Topical treatment of 
MA nanoemulsion in animals with lesions > 6.00 mm also decreased the size of the cutaneous 
lesions, but the described effect did not have statistic support (p=0.12).  
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Effect of topical treatment with MA nanoemulsion or intraperitoneal MA 
on parasite burden 
 
In order to measure the amount of Leishmania parasites in the lesions of infected mice the 
amount of Leishmania specific DNA was determined by Real time PCR. It was assumed that 
there is a direct relationship between the concentration of Leishmania DNA and the degree of 
parasite burden, the greater the concentration of parasite DNA the greater the Leishmania 
present in the lesions. Infected mice treated as indicated in Materials and Methods were 
euthanized and a piece of approximately 3 mm of cutaneous lesion was collected and stored at 
-80°C.  Total DNA was extracted as indicated in materials and methods.  
 
Data indicate that the concentration of Leishmania DNA was greater in the control groups that 
were treated with cream of empty nanoemulsions than in animals treated with MA IP or MA 
nanoemulsion. Due to the great variation of Leishmania DNA concentrations observed within 
the groups the differences between treatments were not statistically different. Although data 
analysis did not show differences in parasitic burden between treatment groups, it is possible 
to observe a tendency for MA IP or MA nanoemulsion to decrease the parasites burden 
(Table5 and Figure3). 
 
Histological analysis 
In order to determine the pathology of the lesions after treatments, lesion samples were taken 
at the end of the experiment. Samples were processed and stained as indicated in materials and 
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methods. For tissue analysis a semi quantitative score was created as described in methods 
section. Data showed no differences for the histological parameter analyzed among groups 
(Table 6). 
 
Side Effects 
 
Weight 
To determine the general health of the animals, weight was monitor throughout the study. 
There were not changes in the weight of the animals due to treatments. Figure 4 shows the 
variation of weight estimated by the delta weight value that was calculated subtracting the 
final minus initial weight of infected mice. There were not statistic differences (p>0.05) in the 
mean of delta values per treatment group. There was a tendency to lose weight in mice treated 
with MA IP injections.  
 
Effect of topical treatment with MA nanoemulsion or intraperitoneal MA 
on blood biochemistry 
 
In order to evaluate the effects of the different MA treatments (IP or topical) on liver, pancreas 
and kidney functions, serum transaminases, alkaline phosphatase and creatinine were 
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measured. For this analysis an extra group of uninfected mice (n=13) that did not received any 
treatment was also included as reference. Serum enzymatic activity of hepatic transaminases 
of animals in the different treatment groups was similar to the uninfected mice. Similarly, 
there were not differences in the concentration of serum creatinine levels among treatment 
groups and uninfected group (Figure 5).  
 
Discussion   
 
The use of liposomes and nanoparticles as means to deliver drugs has produced an 
improvement in pharmacotherapy. Present results suggest that treatment of cutaneous 
leishmaniasis lesions with a nanoemulsion of MA may limit the course of the parasite 
infection. Compared with control treatments cream and nanoemulsion alone, nanoemulsion 
with MA limited the growth of cutaneous lesions. On the other hand MA administered IP 
decreased the size of the lesion. At the same time, the parasite burden in the lesion was also 
controlled in mice that were treated with MA nanoemulsion. 
 
Animals treated with cream and nanoemulsion alone had greater number of parasites (Figure3) 
compared with animals treated with nanoemulsions of MA or IP MA, although the differences 
did not show statistical support.  
 
Amphotericin B desoxycholate in nanoemulsion applied IP showed a greater inhibitory effect 
on Leishmania amastigotes growth than the application of Amphotericin B (p=0,005) without 
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nanoemulsion (17). The authors of these observations indicate that the greater inhibition of the 
parasites maybe due to the improvement in the absorption of the drug in nanoemulsion (17). It 
would be interesting to test the topical administration of Amphotericin B desoxycholate in 
nanoemulsion on cutaneous lesions of leishmaniasis. 
 
Pharmacokinetics studies of intramuscular injections of SbV (active ingredient in MA) in 
hamsters indicate that the drug is rapidly absorbed from the muscle, has a short life in blood of 
approximately 2 hours and readily accumulates in kidneys> liver> skin>spleen > heart, (23). 
The half-life of SbV in skin after intramuscular administration of Sodium stibogluconate (a 
MA equivalent medicine) was approximately 3 hours. Several studies showed that Leishmania 
parasites have not complete eliminated in hamster lesions after 20 days of treatment in spite of 
administered dosis of SbV since 20 mg to 120 mg /Kg of animal weigh. Similarly, the present 
study shows that using a dose of 20mg of SbV/Kg of animal weight for 20 days was not able to 
eliminate all parasites on the lesion (22). In our study, MA in nanoemulsion was applied 
directly in the ulcer to avoid the inconvenience of IM injections and to directly deposit the 
drug in contact with the parasite. The limited effect with MA nanoemulsion to decrease lesion 
size could be the result of an insufficient dose and the liking of the cream after the animal was 
unstrained (see materials and methods). This reduction of the dose is unlikely to occur in 
humans.  It is of interest to study higher doses of topical MA in nanoemulsions and the 
pharmacokinetics of the drug in mice infected with Leishmania. In addition it will be 
interesting to test several local applications of MA to have a better effect against the parasite.  
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The effect on lesion size observed in the different treatment groups, was in agreement with the 
parasite load measured (figure2 and figure3). Control animals that did not received MA had 
higher concentrations of the parasite compared with animals that had MA in nanoemulsion or 
intraperitoneally although the differences were not statistically meaningful. Direct observation 
of histological samples of the different treatment groups showed similar parasitic load among 
treatments. These results were confirmed with Real Time PCR analysis (figure6) which is a 
more efficient method for this evaluation (24).  
 
The mechanism of action of MA to kill Leishmania sp. has not been established yet. It has 
been proposed that Sbv drugs act after their conversion into a more toxic trivalent antimony 
compound within cells of the host or the parasite itself (25). However others indicate that there 
is a direct toxicity effect of Sbv by itself on the parasite (25). Despite of contradictory data, it 
is possible that the effect of Sbv was indirect and results from macrophage – dependent 
reduction to SbIII (4, 25).  In either case, local application of MA could result in a more direct 
exposure of the parasite to the drug. This effect could explain the observation that the size of 
the lesion did not increase in infected animals treated with the MA nanoemulsion. 
 
Treatment of leishmaniasis infection with MA IM is associated with several side effects (1, 4). 
Organs affected by MA treatment include bone morrow, kidneys, liver, heart, and skin (4, 22, 
23). Present study shows that concentrations of ALT, AST, ALKP and creatinine that indicate 
liver and kidney function in animals treated with MA nanoemulsions or IP were similar to 
those observed in animals without Leishmania infection. Also, histological analysis showed 
similar inflammatory processes in all treated groups. Indicating that the local treatment did not 
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provoke a local reaction as observed with some topical agents (26). This response is similar to 
the response reported in other studies that tested topical nanoemulsion application (13-15). 
 
Conclusions 
 
Leishmaniasis is an emergent infectious disease that affects rural areas in tropics and 
subtropics around the world.  Pentavalen antimonials (stibogluconate sodium or MA) are the 
first line treatments against the leishmaniasis infection, but their long term and parenteral 
application have resulted on poor compliance, high toxicity and the development of 
resistantance in parasites to this medicine.   
 
Due to the natural course of cutaneous leishmaniasis infection it is possible to design local 
treatments for this parasitosis. Cutaneous leishmaniasis affects principally exposed skin in 
face, arms or legs. Anti fungal, antibiotics and anti cancer drugs among others have been 
tested to find a new pharmacologic strategy against the leishmaniasis infection. However, 
different reports have shown contradictory results of the application of these alternative drugs. 
Furthermore, cost and several side effects related with dosage and toxicity of medicine 
application result in restrictions of their use and less availability of the medicine. For these 
statements, pentavalen antimonials have not been completely replaced in the leishmaniasis 
treatment in spite of their use for more than 60 years. It is possible that higher concentrations 
and more frequent applications of local nanoemulsions of MA could result in better treatments 
for this infection.   
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Table1. Groups of mice infected with Leishmania spp. classified by applied treatment. 
Groups of mice infected with Leishmania (L.) mexicana MHOM/BE/82/BEL-21 or Leishmania 
(L.) amazonensis MHOM/BR/73/M2269 and treated with 1. Cream alone, 2. Empty 
nanoemulsion ointment, 3. MA nanoemulsion ointment, 4. MA IP administration. n=number 
of infected animals. BEL-21=Leishmania (L) mexicana, M2269 Leishmania (L) amazonensis. 
MA: Meglumine antimonate.  
 
Groups  Treatments 
(n = number of animals) 
Leishmania strain (n) Dose of MA® 
1 Cream alone (n = 6) BEL-21  (n=1) 
M2269   (n=5) 
Control 
2  Empty nanoemulsion ointment  
(n = 12) 
BEL-21   (n=4) 
M2269    (n=8) 
Control 
3  MA  nanoemulsion ointment   (n = 21) BEL-21    (n=8) 
M2269    (n=13) 
20 mg/Kg/d 
4  MA IP  (n = 15) BEL-21   (n=11) 
M2269     (n=4) 
20 mg/Kg/d 
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Table2.  Semi-quantitative scale established for variables in the histological analysis.  
Analysis of histology tissues in BALB/c mice infected skin with Leishmania (L.) mexicana 
MHOM/BE/82/BEL-21 or Leishmania (L.) amazonensis MHOM/BR/73/M2269 were performed in 
a little part of lesion of each mouse after treatment period. The tissue was embedded in paraffin 
block and then it was cut in 4mm layers in order to perform a hematoxylin – eosin stain. These 
stained samples were analyzed by an expert pathologist. Table shows score system for histology 
characteristics classification in mice lesion 
 
Parameter- category 
 
Score classification 
Dermal atrophy 
 
 
Nil Normal tissue 
Mild Decrease of a third in the number of follicles and glands 
Moderate Decrease in two third in the number of follicles and glands 
Severe Absence of follicles and glands 
Hyperkeratosis 
 
Nil Normal tissue 
Mild 1-4 corneal layers 
Moderate 5-10 corneal layers 
Severe More than 10 corneal layers 
Macrophages with parasites 
 
Nil Normal tissue 
Mild 1-8 cells 
Moderate 9-20 cells 
Severe More than 20 cells 
Plasma cells, Lymohocytes , 
polimophonuclear cells and 
Eosinophils infiltration 
Nil Normal tissue 
Mild 1-8 cells 
Moderate 9-20 cells 
Severe More than 20 cells 
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Table3. Real time PCR conditions to determine DNA from Leishmania spp.   
Analysis Mode Cycles Segment Target 
Temperature 
Hold Time Slope °C/s 
   Preincubation   
None 1  95 °C 10 min 20 
   Amplification   
Quantification 45 Denaturation 95°C 10 s 20 
  Anneling 56°C (20uL) 5 s 20 
  Extension  72°C 4,8 s 20 
   Melting curve   
Melting curve 1 Denaturation 95°C 0 s 20 
  Anneling 65°C 30 s 20 
  Extension 95°C 0 s 0.1/s 
   Cooling   
None 1 40°C 30s None 20 
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Table4. Description of lesion size in infected mice. Lesion size was measure before and after 
treatment application. Infected mice were divided in four groups of treatment: 1. Cream alone, 
2. Empty nanoemulsion ointment, 3. MA nanoemulsion ointment, 4. MA IP administration. 
Treatments were started 10 weeks after the initial infection in order to obtain obvious and 
well-defined lesions.  Animals were treated for 20 days. Size of ulcers was monitored every 
week and the measurements at the beginning and at the end of the treatment period were used 
for analysis with a T test. n= number of mice in each group, SD. Standard deviation in mm, p. 
t test p value to evidence the statistic differences between initial and final lesion size in each 
group of mice.  
 
 Treatment Group 
 
N 
Mean 
(mm) SD p 
Cream alone Initial lesion 6 3,83 1,36  
  Final lesion 6 6,07 0,94 0,002 
Empty nanoemulsion ointment Initial lession 12 4,99 1,92  
  Final lesion 12 6,93 2,94 0,001 
MA nanoemulsion Initial lession 21 5,96 1,12  
  Final lesion 21 5,61 1,83 0,455 
MA IP Initial lession 15 6,44 1,40  
  Final lesion 15 4,61 1,47 0,005 
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Table5. Parasite burden in mice skin after treatment period. BALB/c mice infected skin with 
Leishmania (L.) mexicana MHOM/BE/82/BEL-21 or Leishmania (L.) amazonensis 
MHOM/BR/73/M2269 were performed in a little part of lesion of each mouse after treatment 
period. The tissue was frozen at -20°C until DNA extraction. DNA was extracted with High Pure 
PCR Template Preparation kit (Roche Applied Science). To detect the presence of parasite 
specific DNA, real time PCR was performed to amplify a 120-bp DNA fragment from 
Leishmania species kinetoplast minicircles. Parasite in mice skin were quantified using Light 
Cycler 2.0 instrument.  
TREATMENT 
GROUP 
DNA 
(ng/uL) 
PARASITE 
BURDEN MEAN 
TREATMENT 
GROUP 
DNA 
(ng/uL) 
PARASITE 
BURDEN MEAN 
 
 
Cream alone 
(n=5) 
   
 
2,70E+05 
Empty 
Nanoemulsion  
(n=8) 
 
10,76 1,44E+05 
1,41E+05 
23,18 4,36E+04 44,62 1,10E+05 
45,53 2,82E+04 35,67 1,61E+05 
26,79 7,32E+05 16,86 1,28E+05 
43,49 4,50E+04 43,42 1,09E+04 
 
38,75 5,03E+05 
 
31,08 3,33E+05 
    
32,88 8,36E+04 
    
33,56 1,60E+05 
MA 
Nanoemulsion 
(n=15) 
45,75 2,16E+02 
1,54E+05 
    28,82 4,01E+04 
MA injected IP 
(n=14) 
44,25 3,28E+05 
1,03E+05 
39,43 4,13E+05 45,15 3,12E+05 
44,17 1,13E+04 28,82 3,28E+04 
44,77 3,28E+04 45,53 3,23E+03 
30,10 1,07E+05 38,98 4,72E+05 
44,70 4,16E+03 43,49 1,25E+05 
32,88 3,95E+04 46,50 6,34E+02 
38,30 7,15E+04 40,56 5,28E+03 
37,47 6,51E+05 39,13 2,32E+04 
23,93 9,00E+04 45,98 3,96E+01 
39,28 2,22E+05 44,70 6,26E+04 
41,09 2,85E+04 25,51 2,69E+03 
30,55 2,25E+05 32,73 7,18E+04 
17,16 3,75E+05 22,35 6,53E+03 
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Table6. Histological variations reported in BALB/c mice cutaneous lesions.  BALB/c mice 
infected skin with Leishmania (L.) mexicana MHOM/BE/82/BEL-21 or Leishmania (L.) 
amazonensis MHOM/BR/73/M2269 were performed in a little part of lesion of each mouse after 
treatment period. The tissue was embedded in paraffin block and then it was cut in 4mm layers in 
order to perform a hematoxylin – eosin stain. These stained samples were analyzed by an expert 
pathologist. All samples with reports grouped in nil or mild category was defined like negative 
reports for histological variations observed. On the other hand, the presence of changes in 
histology parameters were categorized in groups defines like moderate o severe ones. n= 
represents number of mice.    
                                        Treatment group 
 
Histology issue 
Cream alone 
 n (%) 
Empty nano-
emulsion 
n (%)  
Glucantime-
nanoemulsion 
n (%) 
Glucantime 
IP 
n (%) 
Dermal atrophy 
  
Positive 1(16.7) 1(4.3) 3(18.8) 7(46.7) 
Negative 5 (83.3) 6(85.7) 13(81.3) 8(53.3) 
Hiperkeratosis 
  
Positive 1(16.7) 2(28.6) 1(6.3) 7(46.7) 
Negative 5(83.3) 5 (71.4) 15(93.8) 8(53.3) 
Extracelular parasites 
  
Positive 5(83.3) 7(100) 12(75.0) 12(80.0) 
Positive 1(16.7) 0(0.0) 4(25.0) 3(20.0) 
Linphocyte cells 
infiltration 
  
Positive 3(50.0) 0(0.0) 2(12.5) 6(40.0) 
Negative 3(50.0) 7(100) 14 (87.5) 9(60.0) 
Plasma cells infiltration  Positive 3(50.0) 2(28.6) 4(25.0) 6(40.0) 
Negative 3(50.0) 5(71.4) 12(75.0) 9(60.0) 
Macrophages 
withparasites 
Positive 5(83.3) 7(100) 12(75) 12(80.0) 
Negative 1(16.7) 0 (0.0) 4(25) 3(20.0) 
neutrophyl cells infiltration Positive 2 (33,39 0(0.0) 1(6.3) 3(20.0) 
Negative 4 (66,7) 7(100) 15(93.8) 12(80.0) 
Eosinophil cell 
infiltration  
  
Positive 0(0.0) 0(0.0) 1(6.3) 0(0.0) 
Negative 6(100) 7(100) 15(93.8) 15(100) 
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Figure1. Lesion size differences in infected BALB/c mice. BALB/c mice were infected with 
Leishmania (L.) mexicana MHOM/BE/82/BEL-21 (n=24) or Leishmania (L.) amazonensis 
MHOM/BR/73/M2269 (n-30) were divided in four groups of treatment: 1. Cream alone, 2. 
Empty nanoemulsion ointment, 3. Meglumine antimonate (MA) nanoemulsion ointment, 4. 
Intraperitoneal injections of meglumine antimonate (MA IP). A) Delta values of lesion size. 
This index was calculated by subtracting the largest diameter of the ulcers at the end of the 
treatment period to the largest diameter at the beginning of the study. Increase in lesion size is 
represented by positive values and lesion size decrease is represented by negative values 
(n=55 mice). * Lesion size differences were statistically meaningful (p<0,05). B) Median of 
lesion size: Lesion size in each infected mouse was measured during treatment application 
period (0, 7, 12, 16, 20 days). Median of lesion size for each group of treatment was calculated 
and plotted to observe the changes in lesion trough the treatment period.     
 
 
 
  
 
 
A B 
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 Figure2. Lesion size differences in infected BALB/c with lesion greater than 6.0mm.  
Group of 28 Leishmania infected mice with an initial lesion sizes between 6.0 – 7.8mm was 
selected for a better data analysis. Groups of treatment application were 1. Empty 
nanoemulsion ointment like negative control. 2. Meglumine antimonate (MA) nanoemulsion 
ointment, 3. Intraperitoneal injections of Meglumine antimonate (MA IP). A) The boxes 
represent 1.5 of interquartile range in the distribution of delta values of lesion size. This index 
was calculated by subtracting the largest diameter of the ulcers at the end of the treatment 
period to the largest diameter at the beginning of the study. Increase in lesion size is 
represented by positive values and lesion size decrease is represented by negative values. * 
Lesion size differences were statistically meaningful (p< 0,05). B)  Median of lesion size: 
Lesion size in each infected mouse was measured during treatment application period (0, 7, 
12, 16, 20 days). Median of lesion size for each group of treatment was calculated and plotted 
to observe the changes in lesion trough the treatment period.     
A B 
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Figure3. Parasite burden in BALB/c mice skin after treatment period. At the end of 
treatment period, a group of 28 Balb/c mice infected with Leishmania (L.) mexicana 
MHOM/BE/82/BEL-21 (n=12) or Leishmania (L.) amazonensis MHOM/BR/73/M2269 (n-16) 
with an initial lesion size greater than 6,00 mm, were sacrificed according international 
protocols. Parasite burden was quantified by Real time PCR (Light Cycler 2.0, Roche – 
Diagnostics) in skin samples of each mice cutaneous lesion. Each box represents a different 
treatment group: 1. Negative control (Empty nanoemulsion ointment). 2. Meglumine 
antimonato nanoemulsion. 3. Intraperitoneal administration of Meglumine antomonate. 
Median of parasite burden is represented by an horizontal line inside the boxes. Bars represent 
the 95% of the data in the distribution. (1,75 interquartile range).  
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Figure4. Delta weight index for each mouse infected with Leishmania spp. 54 Balb/c mice 
were infected with Leishmania (L.) mexicana MHOM/BE/82/BEL-21 (n=24) or Leishmania 
(L.) amazonensis MHOM/BR/73/M2269 (n-30). 10 weeks after initial infection mice were 
randomly divided in four treatment group. Groups: 1. Cream alone; 2. Empty nanoemulsion 
ointment; 3. Meglumine antimonate nanoemulsion ointment; 4. Daily IP injection of 
meglumine antimonate in a dosis of 20mg Sbv/Kg/day.  To evaluate the life conditions of mice 
in the experiment, mice weight was weekly registered. The final weight value minus the initial 
one in the treatment period was calculated to obtain a delta weight index. Negative values 
means lose of weight during the treatment period and positive ones means a gain of weight 
during the treatment period.  There were no statistical differences in weight between treatment 
groups. BEL-21: Mice infected with Leishmania (L.) mexicana MHOM/BE/82/BEL-21; 
M2269: Mice infected with Leishmania (L.) amazonensis MHOM/BR/73/M2269; m: mean 
value of delta weight in each treatment group of mice. 
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Figure5. Hepatic enzymes and creatinine results in mice blood after treatment period.  Fifty four 
Balb/c mice infected with Leishmania (L.) mexicana MHOM/BE/82/BEL-21 (n=24) or Leishmania (L.) 
amazonensis MHOM/BR/73/M2269 (n-30) were randomly divided in four treatment groups: 1. Cream 
alone; 2. Empty nanoemulsion ointment; 3. Meglumine antimonate (MA) nanoemulsion ointment; 
4.Intraperitoneal administration of MA (dosis of 20mg Sbv/Kg/day).  To evaluate the toxic effect of 
MA administration, after treatment period blood mice were collected following standard methods in 
animal research. Serum were separated and used for A. Alanine aminotranferase (ALT), B. Aspartate 
aminotransferase (AST), C. Alkaline phosphatase (ALKP) and D. Creatinine analysis (Vitros 250, 
Johnson & Johnson). As reference 13 mice without infection (Group 0) were slaughtered to obtain 
serum for enzyme and creatinine reference values. There were no meaningful differences when enzyme 
and creatinine values were compared between treatment and reference groups. BEL-21: Mice infected 
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with Leishmania (L.) mexicana MHOM/BE/82/BEL-21; M2269: Mice infected with Leishmania (L.) 
amazonensis MHOM/BR/73/M2269; m: mean analite value in each treatment group of mice. 
 
Figure6. Standard curve for quantification of parasite burden by Real Time PCR and 
specific amplification of Leishmania DNA.  At the end of treatment period, a group of 28 
Balb/c mice infected with Leishmania (L.) mexicana MHOM/BE/82/BEL-21 (n=12) or 
Leishmania (L.) amazonensis MHOM/BR/73/M2269 (n-16) with an initial lesion size greater 
than 6,00 mm, were sacrificed according international protocols. Parasite burden was 
quantified by Real time PCR (Light Cycler 2.0, Roche – Diagnostics) in skin samples of each 
mice cutaneous lesion. A) A standard curve for quantification was determined with parasite 
DNA extracted of serial dilutions of counted parasites. The quantification of parasites was 
done through simple count in hemocytometer chamber. B) Mealting peaks resulted of the 
specific amplification of DNA of mice skin sample. The melting temperature for amplification 
of 120-bp fragment of the minicircle kDNA of Leishmania spp. was 84ºC – 86ºC, unspecific 
products could be observed with mealting peaks at 79ºC. 
